Gynecology Therapeutics
1. Orgovyx patent expiration
Treatment: Treatment of adult patients with advanced prostate cancer; Treatment of adult patients with advanced prostate cancer that is sex-hormone-dependent; Treatment of adult patients with advanced prostate c...
ORGOVYX's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7300935 | SUMITOMO PHARMA AM | Thienopyrimidine compounds and use thereof |
Jan, 2029
(3 years from now) | |
| US11795178 | SUMITOMO PHARMA AM | Compositions of thienopyrimidine derivatives |
Sep, 2033
(7 years from now) | |
| US12325714 | SUMITOMO PHARMA AM | Compositions of thienopyrimidine derivatives |
Sep, 2033
(7 years from now) | |
| US8058280 | SUMITOMO PHARMA AM | Substituted thieno[2,3-d]pyrimidin-2,4-dione compounds and uses thereof |
Jan, 2026
(19 days from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11583526 | SUMITOMO PHARMA AM | Treatment of prostate cancer |
Sep, 2037
(11 years from now) | |
| US8735401 | SUMITOMO PHARMA AM | Thienopyrimidine compounds and use thereof |
Feb, 2024
(1 year, 11 months ago) | |
| US12336990 | SUMITOMO PHARMA AM | Treatment of prostate cancer |
Sep, 2037
(11 years from now) | |
| US12144809 | SUMITOMO PHARMA AM | Treatment of prostate cancer |
Sep, 2037
(11 years from now) | |
| US10449191 | SUMITOMO PHARMA AM | Treatment of prostate cancer |
Sep, 2037
(11 years from now) | |
| US10786501 | SUMITOMO PHARMA AM | Treatment of prostate cancer |
Sep, 2037
(11 years from now) | |
| US12097198 | SUMITOMO PHARMA AM | Treatment of prostate cancer |
Sep, 2037
(11 years from now) | |
| US10350170 | SUMITOMO PHARMA AM | Solid preparation |
Feb, 2036
(10 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 18, 2025 |
Drugs and Companies using RELUGOLIX ingredient
NCE-1 date: 18 December, 2024
Market Authorisation Date: 18 December, 2020
Dosage: TABLET
More Information on Dosage
ORGOVYX family patents
2. Osphena patent expiration
Treatment: Treatment of dyspareunia associated with menopause; Treatment of vaginal symptoms of urogenital atrophy by orally administering ospemifene with food to enhance bioavailability of ospemifene; Treatment...
OSPHENA IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9566252 | DUCHESNAY | Method for the alleviation of dyspareunia in women |
Nov, 2022
(3 years ago) | |
| US8470890 | DUCHESNAY | Method for enhancing the bioavailability of ospemifene |
Feb, 2024
(1 year, 10 months ago) | |
| US6245819 | DUCHESNAY | Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause |
Jul, 2025
(5 months ago) | |
| US9855224 | DUCHESNAY | Method for enhancing the bioavailability of ospemifene |
Feb, 2024
(1 year, 10 months ago) | |
| US9241915 | DUCHESNAY | Method for enhancing the bioavailability of ospemifene |
Feb, 2024
(1 year, 10 months ago) | |
| US8772353 | DUCHESNAY | Method for enhancing the bioavalability of ospemifene |
Feb, 2024
(1 year, 10 months ago) | |
| US8236861 | DUCHESNAY | Method for enhancing the bioavailablity of ospemifene |
Aug, 2026
(7 months from now) | |
| US8642079 | DUCHESNAY | Solid formulations of ospemifene |
Jul, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Feb 26, 2018 |
| New Indication(I-793) | Jan 25, 2022 |
Drugs and Companies using OSPEMIFENE ingredient
NCE-1 date: 26 February, 2017
Market Authorisation Date: 26 February, 2013
Dosage: TABLET
How can I launch a generic of OSPHENA before it's drug patent expiration?
More Information on Dosage
OSPHENA family patents
3. Vioxx patent
expiration
Treatment: Relief of the signs and symptoms of osteoarthritis; Relief of the signs and symptoms of rheumatoid arthritis in adults; Management of acute pain in adults; Treatment of primary dysmenorrhea; Acute tre...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5691374 | MERCK | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors |
May, 2015
(10 years ago) | |
|
US5474995 (Pediatric) | MERCK | Phenyl heterocycles as cox-2 inhibitors |
Dec, 2013
(12 years ago) | |
|
US6239173 (Pediatric) | MERCK | 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor |
Dec, 2013
(12 years ago) | |
|
US5691374 (Pediatric) | MERCK | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors |
Nov, 2015
(10 years ago) | |
| US5474995 | MERCK | Phenyl heterocycles as cox-2 inhibitors |
Jun, 2013
(12 years ago) | |
|
US6063811 (Pediatric) | MERCK | Compositions for a once day treatment of cyclooxygenase-2 mediated diseases |
Nov, 2017
(8 years ago) | |
| US6239173 | MERCK | 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor |
Jun, 2013
(12 years ago) | |
| US6063811 | MERCK | Compositions for a once day treatment of cyclooxygenase-2 mediated diseases |
May, 2017
(8 years ago) | |
Drugs and Companies using ROFECOXIB ingredient
Market Authorisation Date: 20 May, 1999
Dosage: TABLET; SUSPENSION
How can I launch a generic of VIOXX before it's drug patent expiration?
More Information on Dosage
VIOXX family patents